>> do you think that trial protocols are designed, in some cases, to prolong the clinical exercise (i.e., delay killing off the compound and preserve funding) <<
Been in biotech since the beginning, and have been very active as an employee and/or investor ever since. The answer to your question is a resounding YES, and we still haven't ridded ourselves of the bait and switch guys.
Over the years, the sector has accumulated some of the least honest individuals on the planet.
(butting in, yes, I know that (1) you asked Peter, and (2) everyone already knows *my* opinion)
:-)
edit: of course, the sector has also attracted those who are most dedicated to a revolution in medicine, many of whom are also ethical. |
